Maridose LLC Activates Bridge to Pharma Strategy to Supply 503B Outsourcing Facilities on Federal Cannabis Rescheduling

DEA-Registered Manufacturer Ready to Serve as the Premier Supplier of Federally Compliant Active Pharmaceutical Ingredients (API) for the Hospital Supply Chain

BRUNSWICK, ME, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- Maridose LLC ("Maridose"), a federally licensed Bulk Manufacturer of controlled substances registered with the U.S. Drug Enforcement Administration (DEA), today announced the deployment of its commercial supply chain strategy. In response to the anticipated rescheduling of cannabis to Schedule III under the Controlled Substances Act, Maridose is initiating strategic partnerships with Section 503B Outsourcing Facilities to ensure immediate, nationwide access to pharmaceutical-grade cannabinoid medicines.

As the United States moves to recognize the medical utility of cannabis, a critical gap remains between federal drug laws and patient access. Maridose is uniquely positioned to bridge this gap. Unlike state-licensed operators who remain restricted by federal interstate commerce bans, Maridose operates under federal jurisdiction. This authorization allows the company to legally transport Active Pharmaceutical Ingredients (API) including high-purity THC and CBD isolates across state lines to DEA-registered partners.

The 503B Advantage: The company’s strategy focuses on the "503B Outsourcing Facility" pathway, a provision of the Drug Quality and Security Act (DQSA) that allows specialized facilities to compound drugs in bulk for hospital and clinical use. This pathway is essential for mitigating drug shortages and providing tailored therapies that FDA-approved products cannot address.

"Rescheduling is the catalyst that transforms cannabis from a localized commodity into a federal pharmaceutical ingredient," said Richard Shain, founder of Maridose. "While the industry awaits the years-long process of new drug approvals, the 503B channel allows us to serve patients today. We are effectively unlocking the national hospital supply chain for cannabinoids. By partnering with 503B facilities, Maridose can supply the raw materials needed to compound critical medications, such as Dronabinol, particularly during periods of manufacturing shortages that threaten patient care."

Operational Readiness: Maridose’s Brunswick, Maine facility is fully operational and compliant with federal security and manufacturing standards. In addition to its domestic manufacturing capabilities, Maridose has obtained import registrations to diversify its controlled substance portfolio, further cementing its status as a robust pharmaceutical supplier. The company also operates an internal Contract Research Organization (CRO) to validate the stability and safety of its API, providing 503B partners with the comprehensive data required for cGMP compliance.

"We are not a cannabis company trying to play pharma; we are a pharmaceutical company that manufactures cannabinoids," added Shain. "Our 503B strategy is the most direct, compliant, and scalable route to bringing botanical medicines into the federal fold. We invite outsourcing facilities and pharmaceutical partners to join us in defining this new standard of care."

About Maridose LLC: Maridose LLC is a DEA-registered Bulk Manufacturer authorized to cultivate, manufacture, import, and export cannabis and other controlled substances for research and pharmaceutical applications. Based in Brunswick, Maine, Maridose leverages advanced science and federal compliance to unlock the therapeutic potential of controlled substances.

Richard Shain
Maridose LLC
Info@maridose.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.